Showing results (171-180 of 504) with videos related to
Sort By:
Pageof 51
Leukemia Research Reports|April 27, 2019
Clonal evolution revealed by next-generation sequencing in a long-term follow-up patient with hypereosinophiliaMeiyu Chen, Jie Liu, Wei Qin, et al.Leukemia Research Reports|May 4, 2019
Central nervous system post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experienceHikaru Sakamoto, Hidehiro Itonaga, Jun Taguchi, et al.Leukemia Research Reports|April 4, 2022
Emergence of t(3;21)(q26.2;q22) during eltrombopag treatment in a patient with relapsed aplastic anemia who received chemotherapy for angioimmunoblastic T-cell lymphomaFumi Nakamura, Yuka Nakamura, Yasuhito Nannya, et al.Leukemia Research Reports|September 29, 2021
CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignanciesJennifer Sun, Yixuan Chen, Berit Lubben, et al.Leukemia Research Reports|March 4, 2022
A new approach in acute myeloid leukemia (AML): Samatya-predicting scoreIstemi Serin, Bagnu Orhan, Derya Sonmez, et al.Leukemia Research Reports|March 7, 2022
Clinical factors predictive of recurrent febrile neutropenia in adult patients with acute leukemiaChinadol Wanitpongpun, Nattiya Teawtrakul, Theerin Lanamtieng, et al.Leukemia Research Reports|April 3, 2023
Effective use of intensive treatment against multiple myeloma of recipient origin after allogeneic transplantation for acute myeloid leukemiaFélicité de Charry, Johanna Konopacki, Sarah Bugier, et al.Leukemia Research Reports|August 21, 2020
Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantationTakahiro Kumode, Shinya Rai, Hirokazu Tanaka, et al.Leukemia Research Reports|August 21, 2020
Isotretinoin is active in the initial management of acute pro-myelocytic leukemiaHusain Y Alkhaldy, Ali M Assiri, Sohaila Fatima, et al.Leukemia Research Reports|June 18, 2014
Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk diseasePamela Paplham, Theresa Hahn, Karen Dubel, et al.Pageof 51